CN1205878A - Compound super-energy calcium - Google Patents
Compound super-energy calcium Download PDFInfo
- Publication number
- CN1205878A CN1205878A CN 98118104 CN98118104A CN1205878A CN 1205878 A CN1205878 A CN 1205878A CN 98118104 CN98118104 CN 98118104 CN 98118104 A CN98118104 A CN 98118104A CN 1205878 A CN1205878 A CN 1205878A
- Authority
- CN
- China
- Prior art keywords
- calcium
- vitamin
- energy
- absorption
- compound super
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The composition of the compound super-energy calcium by 1000 mg calcium element includes calcium carbonate 500-750 mg, vitamin E 80-300mg, vitamin D(D3) 0-200 IU, and calcium chloride 1942-2200mg, or calcium acetate 2765-3160mg or calcium gluconate 7000-9000mg or calcium lactate 4000-5000mg. Owing to containing both soluble calcium salt components with excellent absorption and short duration in blood and slightly soluble calcium salt components with slow absorption and relatively longer duration in blood, the super-energy calcium is favourable to the absorption of tissues. Vitamin E as autogenous estrin can prevent calcium loss and vitamin D(D3) can further improve the absorption and utilization of calcium element.
Description
The present invention relates to compound super-energy calcium.
Calcium is present in the blood plasma and skeleton of human body, and participates in the contraction process of coagulation process and muscle.Calcium is the requisite element of people's bulk-growth.Calcium mostly adopts calcium carbonate and vitamin D at present, and calcium carbonate is insoluble in water, though become ionized calcium (CaCl in gastric acid effect lower part
2), absorb slowly like this, and have part to run off.
The purpose of this invention is to provide a kind of blood medicine degree length of holding time, absorb good compound super-energy calcium.
The present invention takes following measures in order to achieve the above object: the composition of compound super-energy calcium is counted with 1000mg element calcium: calcium carbonate 500～750mg, calcium chloride 1942～2220mg or calcium acetate 2765～3160mg or calcium gluconate 7000～9000mg or calcium lactate 4000～5000mg, vitamin E 80～300mg, vitamin D (D
3) 0～200 iu.
1. advantage of the present invention because the decrease in estrogen of middle aged and aged women causes the bone calcium loss, adopts vitamin E, keeps endogenous estrogen is the powerful measure that stops calcium loss.In addition the male also there is same way clinically.2. because soluble calcium salt (calcium chloride or calcium acetate) absorbs well, and the blood drug level weak point of holding time adds 20～30% slightly solubility element calcium, calcium absorption is slowed down, blood drug level rises slow, and the length of holding time so more helps the absorption and the utilization of tissue to calcium of calcium constituent.3. adopt vitamin D (D
3), further improve the absorption and the utilization of calcium constituent.
Elaborate below in conjunction with embodiment.
Embodiment 1
The composition of compound super-energy calcium is counted with 1000mg element calcium: calcium carbonate 500mg, calcium chloride 2220mg, vitamin e1 00mg, vitamin D (D
3) 50 ius.
Embodiment 2
The composition of compound super-energy calcium is counted with 1000mg element calcium: calcium carbonate 500mg, calcium acetate 3160mg, vitamin e1 00mg, vitamin D (D
3) 50 ius.
Embodiment 3:
The composition of compound super-energy calcium is counted with 1000mg element calcium: calcium carbonate 500mg, calcium gluconate 8000mg, vitamin e1 00mg, vitamin D (D
3) 50 ius.
Embodiment 4:
The composition of compound super-energy calcium is counted with 1000mg element calcium: calcium carbonate 500mg, calcium lactate 4400mg, vitamin e1 00mg, vitamin D (D
3) 50 ius.
Claims (5)
1. a compound super-energy calcium is characterized in that its composition is counted with 1000mg element calcium: calcium carbonate 500～750mg, calcium chloride 1942～2220mg or calcium acetate 2765～3160mg or calcium gluconate 7000～9000mg or calcium lactate 4000～5000mg, vitamin E 80～300mg, vitamin D (D
3) 0～200 iu.
2. a kind of compound super-energy calcium according to claim 1 is characterized in that its composition is counted with 1000mg element calcium: calcium carbonate 500mg, calcium chloride 2220mg, vitamin e1 00mg, vitamin D (D
3) 50 ius.
3. a kind of compound super-energy calcium according to claim 1 is characterized in that its composition is counted with 1000mg element calcium: calcium carbonate 500mg, calcium acetate 3160mg, vitamin e1 00mg, vitamin D (D
3) 50 ius.
4. a kind of compound super-energy calcium according to claim 1 is characterized in that its composition is counted with 1000mg element calcium: calcium carbonate 500mg, calcium gluconate 8000mg, vitamin e1 00mg, vitamin D (D
3) 50 ius.
5. a kind of compound super-energy calcium according to claim 1 is characterized in that its composition is counted with 1000mg element calcium: calcium carbonate 500mg, calcium lactate 4400mg, vitamin e1 00mg, vitamin D (D
3) 50 ius.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98118104 CN1205878A (en) | 1998-07-30 | 1998-07-30 | Compound super-energy calcium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98118104 CN1205878A (en) | 1998-07-30 | 1998-07-30 | Compound super-energy calcium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1205878A true CN1205878A (en) | 1999-01-27 |
Family
ID=5225880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 98118104 Pending CN1205878A (en) | 1998-07-30 | 1998-07-30 | Compound super-energy calcium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1205878A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090939C (en) * | 1999-07-05 | 2002-09-18 | 周竞成 | Calcium ion concentration liquid and process for producing same |
| CN108159073A (en) * | 2018-03-21 | 2018-06-15 | 辽宁千里明药业(集团)有限公司 | A kind of Calci-Mix |
-
1998
- 1998-07-30 CN CN 98118104 patent/CN1205878A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090939C (en) * | 1999-07-05 | 2002-09-18 | 周竞成 | Calcium ion concentration liquid and process for producing same |
| CN108159073A (en) * | 2018-03-21 | 2018-06-15 | 辽宁千里明药业(集团)有限公司 | A kind of Calci-Mix |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9050312B2 (en) | Strontium compound for treatment of sub-dermal soft tissue pain | |
| US6048553A (en) | Aqueous metal bicarbonate solution useful in treating inflammatory, degenerative and viral diseases | |
| US6645948B2 (en) | Nutritional composition for the treatment of connective tissue | |
| AU690377B2 (en) | Application of superoxide dismutase in liposomes | |
| TR200200710T2 (en) | Pharmaceutical liquid compositions produced to prevent the unpleasant taste of the drug. | |
| EP0680945A3 (en) | Amino acid, carnitine and magnesium supplementation | |
| CN1205878A (en) | Compound super-energy calcium | |
| KR0159838B1 (en) | Antianemic agent containing iron and difructose | |
| CA2468664A1 (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain | |
| ES2281669T3 (en) | COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS. | |
| GB2356347B (en) | Pharmaceutical compositions and their use | |
| CO5021217A1 (en) | STABLE COMPOSITIONS OF MITOXANTRONE, PROCEDURE TO PREPARE THEM; USE OF SUCH COMPOSITIONS AND MEDICATIONS THAT INCLUDE SUCH SOLUTIONS FOR THE TREATMENT OF CANCER DISEASES | |
| WO1991016909A1 (en) | Pharmaceutical composition | |
| CA2465471A1 (en) | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction | |
| CN105440088A (en) | Glucosamine mixed strontium salt as well as preparation method and application thereof | |
| Velasco et al. | Reticular erythematous mucinosis and acral papulokeratotic lesions associated with myxoedema due to Hashimoto thyroiditis | |
| JP2005507409A5 (en) | ||
| CN101628112A (en) | Medicament composition for supplementing calcium | |
| CN212140563U (en) | Improved calcaneal anterior process dissection plate | |
| CN116889281A (en) | Hejinyai formula for improving bone mineral density | |
| Lee et al. | The Studies on the Absorption and Excrection of Sulfisoxazole from Alloxan Diabetes States | |
| CN116849785A (en) | Calcaneus fracture steel plate fixing structure and adjusting structure thereof | |
| CN102349977A (en) | External ointment for treating wound pain and preparation method thereof | |
| CN1457814A (en) | Medicine for curing tinea pedis | |
| CN1328828A (en) | Plaster for curing external hemorrhoids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |